MARKET

BIOC

BIOC

Biocept
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.6388
-0.0177
-2.70%
Pre Market 04:31 07/07 EDT
OPEN
0.6665
PREV CLOSE
0.6565
HIGH
0.6670
LOW
0.6210
VOLUME
6.77M
TURNOVER
--
52 WEEK HIGH
1.150
52 WEEK LOW
0.2112
MARKET CAP
83.75M
P/E (TTM)
-0.6861
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average BIOC stock price target is 1.530 with a high estimate of 2.060 and a low estimate of 1.000.

EPS

BIOC News

More
Biocept nabs Canadian patent covering enhanced cell detection methods
Seeking Alpha - Article · 6d ago
Biocept Awarded Canadian Patent Covering the Enhanced Detection of Rare Cells, including Cancer Cells, from a Biological Fluid Sample such as Blood or Cerebrospinal Fluid
PR Newswire · 6d ago
Biocept Awarded Canadian Patent Covering Enhanced Detection Of Rare Cells, Including Cancer Cells, From Biological Fluid Sample Such As Blood Or Cerebrospinal Fluid
Benzinga · 6d ago
Biocepts Covid-19 Testing Capacity Puts It at the Head of the Pack
TipRanks · 06/27 03:04
Biocept Enters Into Agreement with Reference-based Pricing Network Medical Cost Containment Professionals, LLC to Process Out-of-Network Claims
PR Newswire · 06/24 13:05
Biocept partners with managed care provider
Seeking Alpha - Article · 06/24 12:32
Biocept Enters Into Agreement with Reference-Based Pricing Network Medical Cost Containment Professionals, LLC To Process Out-of-Network Claims; Terms Not Disclosed
Biocept Enters Into Agreement with Reference-based Pricing Network Medical Cost Containment Professionals, LLC to Process Out-of-Network Claims SAN DIEGO, June 24, 2020 /PRNewswire/ --Biocept, Inc.
Benzinga · 06/24 12:10
Biocept Announces the Availability of 10,000 Specimen Collection Kits for RT-PCR COVID-19 Testing
PR Newswire · 06/22 13:05

Industry

Medical Equipment, Supplies & Distribution
+0.90%
Healthcare Equipment & Supplies
+1.39%

Hot Stocks

Symbol
Price
%Change

About BIOC

Biocept, Inc. is a molecular oncology diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor deoxyribonucleic acid (ctDNA), assays utilizing a standard blood sample, or liquid biopsy. The Company's Target-Selector offering is based on an internally developed, microfluidics-based CTC capture and analysis platform, with enabling features that change how CTC testing can be used by clinicians by providing biomarker detection and monitoring requiring only a standard blood sample. The ctDNA technology enables mutation detection and is applicable to nucleic acid from CTCs or other sample types, such as blood plasma. The Company commercializes its Target-Selector assays for a range of solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), gastric cancer, colorectal cancer, prostate cancer and melanoma.
More

Webull offers kinds of Biocept Inc stock information, including NASDAQ:BIOC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BIOC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BIOC stock methods without spending real money on the virtual paper trading platform.